Lilly’s oral GLP-1 drug orforglipron cuts A1C and body weight in type 2 diabetes Phase 3 trial
Eli Lilly’s once-daily oral GLP-1 therapy orforglipron delivered significant A1C and weight reductions in Phase 3 ACHIEVE-1 trial, with safety aligned to injectables. Read More
Biomea Fusion posts 15% weight loss in primate model as BMF-650 nears IND for oral GLP-1 therapy
Biomea Fusion’s BMF-650 shows 15% weight loss in primates. Find out why investors are watching its IND filing and Phase I trial timeline for obesity ... Read More
Gan & Lee Pharmaceuticals begins US Phase 2 trial of bofanglutide for obesity and weight management
Gan & Lee Pharmaceuticals (Shanghai Stock Exchange: 603087) has initiated its Phase 2 clinical trial of bofanglutide (GZR18) injection, with the first participant successfully dosed ... Read More
Sun Pharmaceutical’s GL0034 study reveals promising obesity treatment outcomes
Sun Pharmaceutical Industries Limited unveiled data from its Phase 1 study of GL0034 (Utreglutide), targeting obesity in adults. The findings, presented at the 84th American ... Read More